Core Viewpoint - The company Chongqing Pharmaceutical Holdings (重药控股) has received the clinical trial approval notice for its drug, Prasugrel Hydrochloride Tablets, from the National Medical Products Administration (NMPA) of China, indicating progress in its drug development process [1] Group 1 - The company announced on September 12 that it will soon commence clinical trials for Prasugrel Hydrochloride Tablets following the receipt of the approval notice [1] - According to Chinese drug registration laws and regulations, the drug must undergo clinical trials and receive further review and approval from the NMPA before it can be manufactured and marketed [1] - The drug development process is lengthy and involves multiple stages, making it susceptible to various uncertainties [1]

Market Overview - On September 12, the pharmaceutical commercial sector declined by 0.51%, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) leading with a 10.01% increase, closing at 31.31 [1] - Other notable performers included Haiwang Biological (000078) with a 2.69% increase and Runda Medical (603108) with a 1.30% increase [1] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 295 million yuan from institutional investors, while retail investors experienced a net outflow of 113 million yuan [2] - Major stocks like Seer Medical had a significant net inflow of 5.15 billion yuan from institutional investors, while retail investors showed a net outflow of 2.61 billion yuan [2]

Group 1 - Sichuan Road and Bridge's controlling shareholder plans to reduce its stake by up to 2% of the company's total shares, amounting to approximately 174 million shares [1] - Jinlongyu's shareholder terminates the share transfer agreement, halting the planned transfer of 5.32% of the company's shares [1] - Doli Technology's subsidiary plans to establish a joint venture in Spain with an investment of approximately 505 million yuan, with a 70% stake held by Doli Technology [1][2] Group 2 - Chongqing Pharmaceutical, a subsidiary of Zhongyao Holdings, has received approval for clinical trials of its drug, Clopidogrel Hydrochloride Tablets [3][4] - Dongyangguang plans to jointly increase capital in a subsidiary to acquire 100% of Qinhuai Data China for 28 billion yuan [5] - Kangzhi Pharmaceutical's controlling shareholder intends to transfer 5.0004% of the company's shares at a price of 5.34 yuan per share, totaling approximately 122 million yuan [6] Group 3 - Huali Co., Ltd. announces two shareholders plan to reduce their stakes by a combined total of up to 3.96% of the company's shares [7] - Fangbang Co., Ltd.'s director plans to reduce his stake by up to 15,000 shares, representing 0.1844% of the total shares [8] - China Pacific Insurance suggests issuing HKD-denominated convertible bonds, with proceeds aimed at supporting its main insurance business and strategic initiatives [9] Group 4 - Microchip Biotech's shareholder plans to reduce its stake by up to 3% of the company's total shares [10] - Hongbai New Materials' controlling shareholder intends to reduce its stake by up to 3% due to funding needs [11] - Zhejiang Rongtai clarifies that its sales in the robotics components sector are minimal and will not significantly impact annual net profit [12] Group 5 - ST Tianmao voluntarily withdraws its application for A-share listing, which has been accepted by the Shenzhen Stock Exchange [13] - Qingxin Environment's shareholder plans to reduce its stake by up to 1% of the company's total shares [14] - Lanjik Technology's two shareholders plan to reduce their stakes by a combined total of up to 2% of the company's shares [15] Group 6 - BYD's executives and core personnel collectively increased their holdings in the company by approximately 52.33 million yuan [16] - Trina Solar's subsidiary signs contracts for the sale of 2.48 GWh of energy storage products, marking a significant overseas order [17] - Chutianlong's shareholder plans to reduce its stake by up to 3% of the company's total shares [18] Group 7 - Zhongjuxin's shareholder plans to reduce its stake by up to 2.5% of the company's total shares due to funding needs [19] - ST Hezhong's controlling shareholder is under bail pending trial, but company operations remain unaffected [20] - Shoukai Co., Ltd. reports a signed contract amount of 973 million yuan for August, with cumulative contracts of 13.15 billion yuan for the year [21] Group 8 - Jucheng Co., Ltd.'s shareholder plans to reduce its stake by up to 2.61% of the company's total shares due to personal funding needs [22]

Company Overview - Chongqing Pharmaceutical (Group) Co., Ltd., a subsidiary of Zhongyao Holdings, has received the Clinical Trial Approval Notice from the National Medical Products Administration for the drug named Prasugrel Hydrochloride Tablets [1] - Zhongyao Holdings reported a market capitalization of 9 billion yuan [1] Revenue Composition - For the first half of 2025, the revenue composition of Zhongyao Holdings is as follows: 94.81% from pharmaceutical wholesale, 4.73% from pharmaceutical retail, and 0.46% from other businesses [1]

Core Viewpoint - Chongqing Pharmaceutical (Group) Co., Ltd., a subsidiary of Zhongyao Holdings, has received approval from the National Medical Products Administration to conduct clinical trials for its drug, which is currently not available in China [1] Company Summary - Zhongyao Holdings' subsidiary, Chongqing Pharmaceutical, is set to initiate clinical trials for the drug, which is a third-generation platelet aggregation inhibitor [1] - The drug, Prasugrel Hydrochloride Tablets, is indicated for preventing thrombus formation in patients undergoing percutaneous coronary intervention for acute coronary syndrome, stable angina, and old myocardial infarction [1] Industry Summary - The drug is already marketed in over 70 countries and regions globally, indicating its established presence in the international pharmaceutical market [1]

Core Viewpoint - Chongqing Pharmaceutical (Group) Co., Ltd., a subsidiary of Zhongyao Holdings, has received approval from the National Medical Products Administration for clinical trials of Prasugrel Hydrochloride Tablets, marking a significant step in expanding its product portfolio in the cardiovascular drug market [1]. Company Summary - Zhongyao Holdings' subsidiary, Chongqing Pharmaceutical, has been granted a clinical trial approval for Prasugrel Hydrochloride Tablets by the National Medical Products Administration [1]. - Prasugrel Hydrochloride is a third-generation drug that inhibits ADP-induced platelet aggregation, aimed at preventing thrombus formation in patients undergoing percutaneous coronary intervention for acute coronary syndrome, stable angina, and old myocardial infarction [1]. - The original developer of Prasugrel is Daiichi Sankyo Co., Ltd., and the drug is currently available in over 70 countries and regions worldwide, although it has not yet been launched in China [1].

关于子公司药物获临床试验批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 近日，重药控股股份有限公司（以下简称"公司"）控股子公司重庆医药（集 团）股份有限公司（以下简称"重药股份"）收到国家药品监督管理局（以下简称 "国家药监局"）签发的《药物临床试验批准通知书》，将于近期开展临床试验。 现将有关情况公告如下： 证券代码：000950 证券简称：重药控股 公告编号：2025-066 重药控股股份有限公司 二、其他相关情况 盐酸普拉格雷片原研公司为第一三共株式会社，是第三代的抑制 ADP 激活 的血小板聚集的药物，适应于预防接受经皮冠状动脉介入治疗后的急性冠状动脉 综合征、稳定型心绞痛、陈旧性心肌梗塞患者的血栓形成。目前已在全球 70 多 个国家和地区上市（中国境内未上市）。 重药股份投资引进第一三共株式会社的盐酸普拉格雷片技术及独家专利授权， 于 2021 年 8 月提交上市注册申请并获受理。因需进一步完善申报资料，经审慎研 究决定，于 2023 年 7 月主动撤回申请。2025 年 6 月，重药股份临床试验申请获得 受理，具体信息详见公司在巨潮资 ...

Core Viewpoint - Zhongyao Holdings (000950) announced that its subsidiary, Zhongyao Co., has received the clinical trial approval notice from the National Medical Products Administration for the drug Prasugrel Hydrochloride Tablets, which will soon commence clinical trials [1] Company Summary - The drug is indicated for the prevention of thrombus formation in patients undergoing percutaneous coronary intervention for acute coronary syndrome, stable angina, and old myocardial infarction [1]

Core Viewpoint - Chongqing Pharmaceutical (Group) Co., Ltd., a subsidiary of Chongqing Pharmaceutical Holdings, has received the Clinical Trial Approval Notice from the National Medical Products Administration for the drug Prasugrel Hydrochloride Tablets, which is intended for clinical trials [1] Group 1 - The drug Prasugrel Hydrochloride Tablets is a third-generation inhibitor of ADP-induced platelet aggregation [1] - The drug is indicated for the prevention of thrombus formation in patients with acute coronary syndrome after percutaneous coronary intervention, stable angina, and old myocardial infarction [1]

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.29% on September 10, with Dazhenglin leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) rising by 3.99% to a closing price of 28.70, and Dazhenglin (603233) falling by 2.37% to 17.30 [1][2] - Other notable gainers included Guofa Co. (600538) with a 1.65% increase and Dazhangzhang (002462) with a 1.22% increase [1] Trading Volume and Value - Seer Medical had a trading volume of 250,500 shares and a transaction value of 719 million yuan, while Dazhenglin had a trading volume of 77,200 shares and a transaction value of 134 million yuan [1][2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 11.87 million yuan from institutional investors and 50.86 million yuan from speculative funds, while retail investors contributed a net inflow of 62.74 million yuan [2] - Specific stocks like Seer Medical and Jiuzhoutong (600998) had significant net inflows from institutional investors, while others like Yifeng Pharmacy (603939) experienced net outflows from both institutional and speculative funds [3]